#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bone marrow disorder VEXAS syndrome Amyloidosis Hereditary neuropathic amyloidosis Primary adrenal insufficiency Stress cardiomyopathy Hypoxic-ischaemic encephalopathy Synovial sarcoma metastatic Alexander disease Infantile spasms Waldenstrom's macroglobulinaemia refractory Toxic epidermal necrolysis Mantle cell lymphoma Oesophageal achalasia Bronchopulmonary dysplasia More trials…

    Learn about Rare Diseases

    Paraneoplastic neurological syndrome – Trials in Disease Mitochondrial myopathy – Trials in Disease Chondrosarcoma – Diagnostics Netherton’s syndrome – Basic Information Lysosomal storage disorder – Treatment Marginal zone lymphoma – Treatment Propionic acidaemia Lennox-Gastaut syndrome – Basic Information Familial amyotrophic lateral sclerosis – Life with Disease Crigler-Najjar syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Patritumab Deruxtecan Darolutamide Ganirelix Dexketoprofen Bay 3283142 Nvl-655 Apixaban Hexaminolevulinate Carbamazepine OMEGA-3-ACID ETHYL ESTERS 90 Lidocaine Pemetrexed Disodium TEDUGLUTIDE Valproic Acid Immunoglobulin M Tucidinostat L-PROLINE ANGIOTENSIN II Human Immunoglobulin G Gskvx000000008885 More therapies…

    Learn about Your Condition

    Paedophilia Methylmalonic acidaemia Pleomorphic liposarcoma Athetosis Oesophageal disorder Albuminuria Von Hippel-Lindau disease Triple positive breast cancer Behavioural addiction Vasospasm IgA nephropathy Infertility male Juvenile idiopathic arthritis Testicular leiomyosarcoma Precocious puberty More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mpzgxb Zjajrina Kxich 2cr Dmqqdkywn 4goey Hsrkzne

Want to learn more about this study or check if you can participate? Contact us.

  • Study of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Giant cell arteritis
    Investigated Drugs:
    • Secukinumab
    • Prednisone
    Austria Belgium Bulgaria Czechia Denmark Estonia +11

  • Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Palbociclib
    Austria Belgium Germany Hungary Ireland Italy +5

  • Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Bi 706321
    • Ustekinumab
    Czechia Germany Hungary Italy Poland Spain

  • Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Bendamustine
    • Acalabrutinib
    • Cyclophosphamide
    Austria Bulgaria Czechia Denmark France Germany +7

  • Study on the Safety and Effectiveness of Motixafortide and G-CSF for Stem Cell Collection in Patients with Multiple Myeloma

    Not recruiting

    3 1
    Investigated Drugs:
    • Motixafortide
    Germany Hungary Italy Spain

  • Study on the Effects of Ianalumab with Standard Therapy for Patients with Active Lupus Nephritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lupus nephritis
    Investigated Drugs:
    • Entecavir
    • Ianalumab
    • Mycophenolic Acid
    Czechia Estonia France Germany Hungary Italy +3

  • Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

    Not recruiting

    3 1
    Investigated Drugs:
    • Iptacopan
    Belgium Czechia Denmark France Germany Hungary +6

  • Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Ruxolitinib
    Belgium Bulgaria France Germany Hungary Italy +3

  • Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Embolism venous
    Investigated Drugs:
    • Abelacimab
    • Apixaban
    Austria Czechia France Germany Hungary Ireland +6

  • Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Embolism venous
    • Gastrointestinal cancer metastatic
    Investigated Drugs:
    • Abelacimab
    • Dalteparin Sodium
    Austria Czechia France Germany Hungary Ireland +6
Previous Page
1 … 28 29 30 31 32 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!